[go: up one dir, main page]

WO2002067863A3 - Tolerogenic antigen presenting cells and in treating immune-inflammatory conditions - Google Patents

Tolerogenic antigen presenting cells and in treating immune-inflammatory conditions Download PDF

Info

Publication number
WO2002067863A3
WO2002067863A3 PCT/US2002/005441 US0205441W WO02067863A3 WO 2002067863 A3 WO2002067863 A3 WO 2002067863A3 US 0205441 W US0205441 W US 0205441W WO 02067863 A3 WO02067863 A3 WO 02067863A3
Authority
WO
WIPO (PCT)
Prior art keywords
antigen presenting
presenting cells
tolerogenic antigen
immune
inflammatory conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/005441
Other languages
French (fr)
Other versions
WO2002067863A2 (en
Inventor
Joan Stein-Streilein
J Wayne Streilein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Schepens Eye Research Institute Inc
Original Assignee
Schepens Eye Research Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schepens Eye Research Institute Inc filed Critical Schepens Eye Research Institute Inc
Priority to AU2002252073A priority Critical patent/AU2002252073A1/en
Priority to US10/468,944 priority patent/US20040076604A1/en
Publication of WO2002067863A2 publication Critical patent/WO2002067863A2/en
Anticipated expiration legal-status Critical
Publication of WO2002067863A3 publication Critical patent/WO2002067863A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A61K39/36—Allergens from pollen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4225—Growth factors
    • A61K40/4229—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C12N5/064—Immunosuppressive dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention is directed to the preparation and use of tolerogenic antigen presenting cells as a method of down-regulating an immune response in a patient who has an established immune-inflammatory condition or who is at risk of suffering from an immune-inflammatory condition. The tolerogenic antigen presenting cells re-educate patient's own defense cells not only to suppress secretion of cytokines that generates an inflammatory response, but also to stimulate the secretion of immunosuppressive agents to ameliorate debilitating immune effects.
PCT/US2002/005441 2001-02-22 2002-02-22 Tolerogenic antigen presenting cells and in treating immune-inflammatory conditions Ceased WO2002067863A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2002252073A AU2002252073A1 (en) 2001-02-22 2002-02-22 Tolerogenic antigen presenting cells and in treating immune-inflammatory conditions
US10/468,944 US20040076604A1 (en) 2002-02-22 2002-02-22 Tolergenic antigen presenting cells and in treating immune-inflammatory conditions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27061601P 2001-02-22 2001-02-22
US60/270,616 2001-02-22

Publications (2)

Publication Number Publication Date
WO2002067863A2 WO2002067863A2 (en) 2002-09-06
WO2002067863A3 true WO2002067863A3 (en) 2004-02-12

Family

ID=23032065

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/005441 Ceased WO2002067863A2 (en) 2001-02-22 2002-02-22 Tolerogenic antigen presenting cells and in treating immune-inflammatory conditions

Country Status (2)

Country Link
AU (1) AU2002252073A1 (en)
WO (1) WO2002067863A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080090413A (en) * 2005-12-08 2008-10-08 유니버시티 오브 루이빌 리서치 파운데이션, 인코포레이티드 Methods and Compositions for Expansion of T Regulatory Cells
AU2012301814A1 (en) 2011-08-31 2014-02-27 Perosphere Technologies Inc. Methods for effectively and rapidly desensitizing allergic patients
PL2768942T3 (en) 2011-10-17 2020-05-18 Massachusetts Institute Of Technology Intracellular delivery
US10124336B2 (en) 2013-08-16 2018-11-13 Massachusetts Institute Of Technology Selective delivery of material to cells
SG10201903912XA (en) 2014-10-31 2019-05-30 Massachusetts Inst Technology Delivery of biomolecules to immune cells
WO2016077761A1 (en) 2014-11-14 2016-05-19 Massachusetts Institute Of Technology Disruption and field enabled delivery of compounds and compositions into cells
WO2016115179A1 (en) 2015-01-12 2016-07-21 Massachusetts Institute Of Technology Gene editing through microfluidic delivery
EP3320082B1 (en) 2015-07-09 2023-05-24 Massachusetts Institute of Technology Delivery of materials to anucleate cells
WO2017041051A1 (en) 2015-09-04 2017-03-09 Sqz Biotechnologies Company Intracellular delivery of biomolecules to cells comprising a cell wall
JP7602702B2 (en) 2016-05-03 2024-12-19 ステムセル テクノロジーズ カナダ インコーポレーテッド Intracellular delivery of biomolecules to induce tolerance
SG11201809617RA (en) * 2016-05-03 2018-11-29 Sqz Biotechnologies Co Intracellular delivery of biomolecules to induce tolerance
WO2020176789A1 (en) 2019-02-28 2020-09-03 Sqz Biotechnologies Company Delivery of biomolecules to pbmcs to modify an immune response

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
KEZUKA T. ET AL.: "Analysis of in vivo regulatory properties of T cells activated in vitro by TGF-beta2-treated antigen presenting cells", INVEST. OPTHALMOL. VIS. SCI., vol. 41, no. 6, May 2000 (2000-05-01), pages 1410 - 1421, XP002954811 *
STEINBRINK K. ET AL.: "Induction of tolerance by IL-10 treated dendritic cells", J. IMMUNOL., vol. 159, 1997, pages 4772 - 4780, XP002954806 *
STEINBRINK K. ET AL.: "Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific energy in CD8+ T cells resulting in a failure to lyse tumor cells", BLOOD, vol. 93, no. 5, 1 March 1999 (1999-03-01), pages 1634 - 1642, XP002954809 *
STROBL H. ET AL.: "TGF-beta regulation of dendritic cells", MICROBES INFEC., vol. 1, 1999, pages 1283 - 1290, XP002954810 *
TAKEUCHI M. ET AL.: "On the mechanisms by which transforming growth factor-beta2 alters antigen-presenting abilities of macrophages on T cell activation", EUR. J. IMMUNOL., vol. 27, 1997, pages 1648 - 1656, XP002954807 *
TAKEUCHI M. ET AL.: "TGF-beta promotes immune deviation by altering accessory signals of antigen-presenting cells", J. IMMUNOL., vol. 160, 1998, pages 1589 - 1597, XP002954808 *

Also Published As

Publication number Publication date
WO2002067863A2 (en) 2002-09-06
AU2002252073A1 (en) 2002-09-12

Similar Documents

Publication Publication Date Title
WO2002067863A3 (en) Tolerogenic antigen presenting cells and in treating immune-inflammatory conditions
PL1660458T3 (en) 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
HUP0401023A3 (en) Use of flibanserin in the treatment of sexual disorders
WO2000023955A8 (en) Virus-like particles for the induction of autoantibodies
WO2003047524A3 (en) Methods and compositions for modulating the immune system and uses thereof
IL151946A0 (en) 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders
EP1352897A3 (en) Adamantane derivatives for the treatment of inflammatory, immune and cardiovascular diseases
AU2002322478A1 (en) Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
AU2002339128A1 (en) Use of reelin, gas6, and protein s in the treatment of neural disorders
AU7528001A (en) The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
WO2001051008A3 (en) Selective activation of a th1 or th2 lymphocyte regulated immune response
AU2002347152A8 (en) Immune globulin formulations for the treatment and prevention of an orthopoxvirus infection
AU5754701A (en) Method of using cox-2 inhibitors in the treatment and prevention of ocular cox-2mediated disorders
AU2001256855A1 (en) Preparation for the prevention and treatment of ocular disorders
MXPA03003741A (en) Methods and compositions for the treatment of diseases of the eye.
IL131179A0 (en) Substituted (1,3-bis(cyclohexylmethyl)-1,2,3,6-tetrahydro-2,6-dioxo-9h-purin-8-yl) phenyl derivatives their preparation and their use in the treatment of inflammatory conditions and immune disorders
WO2003018606A3 (en) Casein derived peptides and uses thereof in therapy
NZ504955A (en) The use of TH1 and TH2 cytokines for the preparation of an oromucosal medicament
PL366906A1 (en) Imidazotriazinones derivatives and their use against inflammatory processes and/or immune diseases
WO2002036124A3 (en) Treatment and method using loratadine and montelukast
IL123922A (en) Detection, prevention and treatment of papillomatous digital dermatitis in ruminants comprising a therapeutically effective amount of serpens spp
WO2005042028A3 (en) Il-13 conjugated to an immunogen and uses thereof
WO2000077177A3 (en) Isolation of a human retrovirus
MD2053B1 (en) Remedy with interferon inducing action
AU2001285026A1 (en) Methods and compositions for use in the diagnosis and treatment of chronic immune disease

Legal Events

Date Code Title Description
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10468944

Country of ref document: US

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP